KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Globus Medical (GMED) Depreciation and Depletion (2018 - 2025)

Globus Medical (GMED) has disclosed Depreciation and Depletion for 7 consecutive years, with $40.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation and Depletion rose 5.15% year-over-year to $40.3 million, compared with a TTM value of $159.3 million through Dec 2025, up 18.29%, and an annual FY2025 reading of $159.3 million, up 18.3% over the prior year.
  • Depreciation and Depletion was $40.3 million for Q4 2025 at Globus Medical, down from $41.3 million in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $43.0 million in Q4 2023 and bottomed at $12.2 million in Q3 2021.
  • Average Depreciation and Depletion over 5 years is $24.5 million, with a median of $19.1 million recorded in 2021.
  • The sharpest move saw Depreciation and Depletion fell 13.59% in 2022, then skyrocketed 246.98% in 2023.
  • Year by year, Depreciation and Depletion stood at $12.3 million in 2021, then increased by 1.06% to $12.4 million in 2022, then surged by 246.98% to $43.0 million in 2023, then dropped by 10.98% to $38.3 million in 2024, then grew by 5.15% to $40.3 million in 2025.
  • Business Quant data shows Depreciation and Depletion for GMED at $40.3 million in Q4 2025, $41.3 million in Q3 2025, and $40.4 million in Q2 2025.